| 2025-10-31 |
详情>>
股本变动：
变动后总股本10061.60万股
|
| 2025-10-31 |
详情>>
业绩披露：
2025年三季报(累计)每股收益4.17美元,归母净利润4.20亿美元,同比去年增长25.48%
|
| 2025-10-29 |
财报披露：
美东时间 2025-10-29 盘后发布财报
|
| 2025-10-15 |
详情>>
内部人交易：
Reidy Christopher R等共交易2笔
|
| 2025-08-06 |
详情>>
业绩披露：
2025年中报每股收益2.91美元,归母净利润2.94亿美元,同比去年增长29.57%
|
| 2025-05-01 |
详情>>
业绩披露：
2025年一季报每股收益1.50美元,归母净利润1.51亿美元,同比去年增长34.67%
|
| 2025-04-01 |
股东大会：
将于2025-05-01召开股东大会
会议内容 ▼▲
- 1.To elect 10 directors to the board of directors to serve until our 2026 annual meeting of stockholders.
2.To ratify the appointment by Encompass Health’s Audit Committee of PricewaterhouseCoopers LLP as Encompass Health’s independent registered public accounting firm.
3.To approve, on an advisory basis, the compensation of the named executive officers as disclosed in Encompass Health’s Definitive Proxy Statement for the 2025 annual meeting.
4.To approve the 2025 Omnibus Performance Incentive Plan.
5.To transact such other business as may properly come before the annual meeting and any adjournment or postponement.
|
| 2025-02-28 |
详情>>
业绩披露：
2022年年报每股收益2.72美元,归母净利润2.71亿美元,同比去年增长-34.26%
|
| 2025-02-28 |
详情>>
业绩披露：
2024年年报每股收益4.53美元,归母净利润4.56亿美元,同比去年增长29.46%
|
| 2024-11-01 |
详情>>
业绩披露：
2024年三季报(累计)每股收益3.33美元,归母净利润3.35亿美元,同比去年增长26.63%
|
| 2024-08-06 |
详情>>
业绩披露：
2023年中报每股收益1.79美元,归母净利润1.79亿美元,同比去年增长31.50%
|
| 2024-08-06 |
详情>>
业绩披露：
2024年中报每股收益2.25美元,归母净利润2.27亿美元,同比去年增长26.52%
|
| 2024-05-02 |
详情>>
业绩披露：
2024年一季报每股收益1.12美元,归母净利润1.12亿美元,同比去年增长28.28%
|
| 2024-04-02 |
股东大会：
将于2024-05-02召开股东大会
会议内容 ▼▲
- 1.To elect 10 directors to the board of directors to serve until our 2025 annual meeting of stockholders.
2.To ratify the appointment by Encompass Health’s Audit Committee of PricewaterhouseCoopers LLP as Encompass Health’s independent registered public accounting firm.
3.To approve, on an advisory basis, the compensation of the named executive officers as disclosed in Encompass Health’s Definitive Proxy Statement for the 2024 annual meeting.
4.To vote on a stockholder proposal requesting a report on the effectiveness of the Company’s diversity, equity, and inclusion efforts.
5.To transact such other business as may properly come before the annual meeting and any adjournment or postponement.
|
| 2024-02-28 |
详情>>
业绩披露：
2023年年报每股收益3.51美元,归母净利润3.52亿美元,同比去年增长29.89%
|
| 2023-11-01 |
详情>>
业绩披露：
2023年三季报(累计)每股收益2.64美元,归母净利润2.64亿美元,同比去年增长45.59%
|
| 2023-04-03 |
股东大会：
将于2023-05-04召开股东大会
会议内容 ▼▲
- 1.To elect 11 directors to the board of directors to serve until our 2024 annual meeting of stockholders.
2.To ratify the appointment by Encompass Health’s Audit Committee of PricewaterhouseCoopers LLP as Encompass Health’s independent registered public accounting firm.
3.To approve, on an advisory basis, the compensation of the named executive officers as disclosed in Encompass Health’s Definitive Proxy Statement for the 2023 annual meeting.
4.To vote, on an advisory basis, as to whether the above “say-on-pay” advisory vote should occur every one, two, or three years.
5.To transact such other business as may properly come before the annual meeting and any adjournment or postponement.
|
| 2022-04-04 |
股东大会：
将于2022-05-05召开股东大会
会议内容 ▼▲
- 1.To elect 11 directors to the board of directors to serve until our 2023 annual meeting of stockholders.The board of directors recommends a vote FOR each nominee.
2.To ratify the appointment by Encompass Health’s Audit Committee of PricewaterhouseCoopers LLP as Encompass Health’s independent registered public accounting firm.The board of directors recommends a vote FOR ratification.
3.To approve, on an advisory basis, the compensation of the named executive officers as disclosed in Encompass Health’s Definitive Proxy Statement for the 2022 annual meeting.The board of directors recommends a vote FOR the approval of the compensation of our named executive officers.
4.To transact such other business as may properly come before the annual meeting and any adjournment or postponement.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-03-26 |
股东大会：
将于2021-05-06召开股东大会
会议内容 ▼▲
- 1.To elect 14 directors to the board of directors to serve until our 2022 annual meeting of stockholders.
2.To ratify the appointment by Encompass Health’s Audit Committee of PricewaterhouseCoopers LLP as Encompass Health’s independent registered public accounting firm.
3.To approve, on an advisory basis, the compensation of the named executive officers as disclosed in Encompass Health’s Definitive Proxy Statement for the 2021 annual meeting.
4.To transact such other business as may properly come before the annual meeting and any adjournment or postponement.
|
| 2020-03-27 |
股东大会：
将于2020-05-06召开股东大会
会议内容 ▼▲
- 1.To elect fourteen directors to the board of directors to serve until our 2020 annual meeting of stockholders.
2.To ratify the appointment by Encompass Health’s Audit Committee of PricewaterhouseCoopers LLP as Encompass Health’s independent registered public accounting firm.
3.To approve, on an advisory basis, the compensation of the named executive officers as disclosed in Encompass Health’s Definitive Proxy Statement for the 2020 annual meeting.
named executive officers.
4.To transact such other business as may properly come before the annual meeting and any adjournment or postponement.
|
| 2020-02-20 |
除权日：
美东时间 2020-03-31 每股派息0.28美元
|
| 2019-10-25 |
除权日：
美东时间 2019-12-31 每股派息0.28美元
|
| 2019-07-23 |
除权日：
美东时间 2019-09-30 每股派息0.28美元
|
| 2019-05-03 |
除权日：
美东时间 2019-06-28 每股派息0.27美元
|
| 2019-03-21 |
股东大会：
将于2019-05-03召开股东大会
会议内容 ▼▲
- 1.To elect eleven directors to the board of directors to serve until our 2020 annual meeting of stockholders.
2.To ratify the appointment by Encompass Health’s Audit Committee of PricewaterhouseCoopers LLP as Encompass Health’s independent registered public accounting firm.
3.To approve, on an advisory basis, the compensation of the named executive officers as disclosed in Encompass Health’s Definitive Proxy Statement for the 2019 annual meeting.
4.To transact such other business as may properly come before the annual meeting and any adjournment or postponement.
|
| 2019-02-21 |
除权日：
美东时间 2019-03-29 每股派息0.27美元
|
| 2018-10-26 |
除权日：
美东时间 2018-12-31 每股派息0.27美元
|
| 2018-07-24 |
除权日：
美东时间 2018-09-28 每股派息0.27美元
|
| 2018-05-04 |
除权日：
美东时间 2018-06-29 每股派息0.25美元
|
| 2018-03-23 |
股东大会：
将于2018-05-03召开股东大会
会议内容 ▼▲
- 1.To elect eleven directors to the board of directors to serve until our 2019 annual meeting of stockholders.
2.To ratify the appointment by Encompass Health’s Audit Committee of PricewaterhouseCoopers LLP as Encompass Health’s independent registered public accounting firm.
3.To approve, on an advisory basis, the compensation of the named executive officers as disclosed in Encompass Health’s Definitive Proxy Statement for the 2018 annual meeting.
4.To transact such other business as may properly come before the annual meeting and any adjournment or postponement.
|
| 2018-02-23 |
除权日：
美东时间 2018-03-29 每股派息0.25美元
|
| 2017-10-31 |
除权日：
美东时间 2017-12-29 每股派息0.25美元
|
| 2017-07-31 |
除权日：
美东时间 2017-09-29 每股派息0.25美元
|
| 2017-05-04 |
除权日：
美东时间 2017-06-29 每股派息0.24美元
|
| 2017-03-24 |
股东大会：
将于2017-05-04召开股东大会
会议内容 ▼▲
- 1.To elect ten directors to the board of directors to serve until our 2018 annual meeting of stockholders.
2.to ratify the appointment by the Audit Committee of our board of directors of PricewaterhouseCoopers LLP as our independent registered public accounting firm;
3.to approve, on an advisory basis, the compensation of the named executive officers, as disclosed in this proxy statement for the 2017 annual meeting;
4.to vote, on an advisory basis, as to whether the above “say on pay” advisory vote should occur every one, two, or three years;
5.to transact such other business as may properly come before the 2017 annual meeting of stockholders and any adjournment or postponement.
|
| 2017-02-17 |
除权日：
美东时间 2017-03-30 每股派息0.24美元
|
| 2016-10-20 |
除权日：
美东时间 2016-12-29 每股派息0.24美元
|
| 2016-07-21 |
除权日：
美东时间 2016-09-29 每股派息0.24美元
|
| 2016-05-06 |
除权日：
美东时间 2016-06-29 每股派息0.23美元
|
| 2016-04-29 |
除权日：
美东时间 2016-03-30 每股派息0.23美元
|
| 2016-04-05 |
股东大会：
将于2016-05-05召开股东大会
会议内容 ▼▲
- (1)to elect ten directors to the board of directors to serve until our 2017 annual meeting of stockholders;
(2)to ratify the appointment by the Audit Committee of our board of directors of PricewaterhouseCoopers LLP as our independent registered public accounting firm;
(3)to approve, on an advisory basis, the compensation of the named executive officers, as disclosed in this proxy statement for the 2016 annual meeting;
(4)to approve the 2016 Omnibus Performance Incentive Plan;
(5)to transact such other business as may properly come before the 2016 annual meeting of stockholders and any adjournment or postponement.
|
| 2015-10-26 |
除权日：
美东时间 2015-12-29 每股派息0.23美元
|
| 2015-07-17 |
除权日：
美东时间 2015-09-29 每股派息0.23美元
|
| 2015-05-08 |
除权日：
美东时间 2015-06-29 每股派息0.21美元
|
| 2015-02-20 |
除权日：
美东时间 2015-03-30 每股派息0.21美元
|
| 2014-10-21 |
除权日：
美东时间 2014-12-30 每股派息0.21美元
|